Scarica l'app Stockscreener
0.9402
3.07%
-0.0298
Dopo l'orario di chiusura:
.96
0.0198
+2.11%
Precedente Chiudi:
$0.97
Aprire:
$0.98
Volume 24 ore:
149.60K
Relative Volume:
0.36
Capitalizzazione di mercato:
$3.35M
Reddito:
-
Utile/perdita netta:
$-11.89M
Rapporto P/E:
-0.1669
EPS:
-5.6317
Flusso di cassa netto:
$-10.96M
1 W Prestazione:
-18.24%
1M Prestazione:
-29.31%
6M Prestazione:
-80.00%
1 anno Prestazione:
-93.37%
Intervallo 1D:
$0.85
$1.005
Intervallo di 1 settimana:
$0.85
$1.16
Portata 52W:
$0.85
$14.64
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Nome
Cadrenal Therapeutics Inc
Settore
Industria
Telefono
904-300-0701
Indirizzo
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
0.9402 | 4.10M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-18 | Iniziato | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Borsa (CVKD) Ultime notizie
Cadrenal Therapeutics Shareholders Approve 323,542-Share Equity Plan Increase - Minichart
Cadrenal Therapeutics shareholders approve equity plan amendment and warrant issuance - Investing.com
Cadrenal Shareholders Approve Equity Plan and Board Changes - TipRanks
Form 8K Cadrenal Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics CEO to Present at Lytham Partners Fall 2026 Investor Conference - Quiver Quantitative
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference - GlobeNewswire
Cadrenal Therapeutics (CVKD) Slips 4.46% to $1.07, Drifting Toward Lower SupportSystematic Flow - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Stock Price, Quote, News & History - benzinga.com
Cadrenal Therapeutics announces up to $8.8M private placement - scanx.trade
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference - Yahoo Finance
Cadrenal Therapeutics advances CAD-1005 Phase 3 pathway - TipRanks
Cadrenal Therapeutics (CVKD) Advances Phase 3 Trial Protocol, Fa - GuruFocus
Cadrenal Therapeutics Announces FDA Alignment on Phase 3 Primary Endpoint for CAD-1005 HIT Study - Quiver Quantitative
FDA agrees to a placebo trial for a drug aimed at a blood reaction affecting 50,000 yearly - Stock Titan
CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise - Yahoo Finance
Cadrenal's CAD-1005 cuts thrombotic events by over 25% in Phase 2 - scanx.trade
Cadrenal (CVKD) Results Check: EPS Clears the Reported Estimate; After Results: Shares Move 4.09% Down on the DayEarnings Recovery Stocks - dars.gov.et
Cadrenal (CVKD) Latest Earnings Reading: The Bottom-Line Figure Beats Its Comparison in the Current Update; Post-Report Move: Shares Finish 2.29% Lower at the CloseFull Year Guidance - vinanet.vn
Cadrenal Therapeutics (CVKD) Falls 4.28% to $1.79, Pressing Against Key SupportFibonacci Entry Signals - vinanet.vn
Avoiding Lag: Real-Time Signals in (CVKD) Movement - Stock Traders Daily
Cadrenal Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cadrenal Maintained at Buy as Partnership-Focused Strategy Supports Unchanged $13 Price Target - TipRanks
Cadrenal to seek FDA pediatric designation for tecarfarin - scanx.trade
Cadrenal Therapeutics data on CAD-1005 accepted for ISTH presentation - scanx.trade
PNC Financial Services Group, Inc. Acquires New Stake in Cadrenal Therapeutics Inc (CVKD) - GuruFocus
Cadrenal Therapeutics appoints John P. Sharp as interim CFO - scanx.trade
Cadrenal Therapeutics Q2 Results: Net Loss Narrows To $3.3 Million - scanx.trade
Cadrenal Therapeutics reports Q2 2026 net loss of $3.3M; cash runway into Q1 2027 - TradingView
Cadrenal CAD-1005 data show more than 25% absolute drop in clot events - Stock Titan
Cadrenal Therapeutics (CVKD) Q1 2026 Earnings: Wider-Than-Expected Loss Buffer Despite Stock DipEstimate Dispersion - Vinanet
Cadrenal Therapeutics (CVKD) Slides 7.5% to $1.84 — Testing Critical Support at $1.75Passive Flow - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a shareEarnings Preview - TradingView
Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client - Stock Titan
CVKD | Cadrenal Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Cadrenal Therapeutics (CVKD) Slips 2.49% to $1.96 as Shares Test Range-Bound SupportAI Trade Signals - dars.gov.et
CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy - Smartkarma
Cadrenal expands CAD-1005 development to two indications - Investing.com
Cadrenal expands CAD-1005 development to two indications By Investing.com - Investing.com India
Cadrenal Therapeutics Highlights CAD-1005 as Dual-Indication 12-LOX Inhibitor for HIT and CSA-AKI Following Competing Trial Failure - Quiver Quantitative
Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation - Yahoo Finance
Cadrenal Therapeutics (CVKD) Drops 3.8%, Approaches Critical $1.91 SupportMean Reversion Trade - dars.gov.et
Cadrenal Therapeutics Inc (CVKD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cadrenal Therapeutics Inc (CVKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cadrenal Therapeutics Inc (CVKD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:1.830|Chg%:-0.030 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cadrenal Therapeutics Inc (CVKD) Institutional Confidence - TradingKey
Cadrenal Therapeutics Inc (CVKD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CVKD|Cadrenal Therapeutics Inc|Price:2.045|Chg%:-0.015 - TradingKey
Cadrenal Therapeutics Inc (CVKD) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Cadrenal Therapeutics Inc Azioni (CVKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cadrenal Therapeutics Inc Azioni (CVKD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 26 '26 |
Sale |
3.05 |
9,029 |
27,538 |
105,989 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 25 '26 |
Sale |
3.00 |
2,127 |
6,381 |
115,018 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 22 '26 |
Sale |
3.55 |
9,167 |
32,543 |
119,422 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 23 '26 |
Sale |
3.20 |
2,277 |
7,286 |
117,145 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 16 '26 |
Sale |
3.18 |
3,613 |
11,489 |
129,102 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 17 '26 |
Sale |
3.16 |
513 |
1,621 |
128,589 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 12 '26 |
Sale |
3.94 |
12,996 |
51,204 |
136,381 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 15 '26 |
Sale |
3.58 |
3,666 |
13,124 |
132,715 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 11 '26 |
Sale |
4.12 |
1,462 |
6,023 |
149,377 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):